Skip to main content

Candel Therapeutics, Inc.

CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001841387

In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Candel Therapeutics, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of CADL: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders8278−4
Shares21.2M23.0M+1.85M (+8.7%)
Value$119.7M$116.6M−$3.16M (−2.6%)

New holders (16)

Institutions that held Candel Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to CADL in Q2 2025
InstitutionSharesValue% of portfolio
Two Sigma Investments, LP369,195$1.87M0.00%
Tanager Wealth Management LLP196,631$995.0K0.12%
Renaissance Technologies LLC163,600$827.8K0.00%
Wellington Management Group LLP86,247$436.4K0.00%
XTX Topco Ltd74,629$377.6K0.02%
LPL Financial LLC67,893$343.5K0.00%
Bridgeway Capital Management, LLC55,100$278.8K0.01%
Two Sigma Advisers, LP36,485$184.6K0.00%
Cubist Systematic Strategies, LLC28,475$144.1K0.00%
Alps Advisors Inc27,045$136.8K0.00%
Los Angeles Capital Management LLC24,810$125.5K0.00%
Boreal Capital Management LLC16,000$81.0K0.07%
Manufacturers Life Insurance Company, The13,826$70.0K0.00%
Voya Investment Management LLC10,981$55.6K0.00%
Close Asset Management Ltd1,350$7.00K0.00%
Point72 (DIFC) Ltd146$7400.00%

Sold out (20)

Institutions that held Candel Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.